Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer
Sue Jin Moon, Byong Chang Jeong, Hwa Jin Kim, Joung Eun Lim, Hyejeong Kim, Ghee Young Kwon, Joshua A. Jackman, Jeong Hoon Kim
Abstract
Our findings suggest that BCT could serve as a promising therapeutic candidate against CRPC and highlight the potential benefit of targeting AR-FL/AR-V7-HSP90 axis to overcome resistance caused by aberrant AR-FL/AR-V7 signaling.
Topics & Concepts
Prostate cancerCastrationOncologyMedicineInternal medicineHormone therapyHormoneCancerCancer researchBreast cancerHeat shock proteins researchToxin Mechanisms and ImmunotoxinsEndoplasmic Reticulum Stress and Disease